These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620 [TBL] [Abstract][Full Text] [Related]
5. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis. Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607 [TBL] [Abstract][Full Text] [Related]
6. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3 NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT. Miere A; Querques G; Semoun O; Amoroso F; Zambrowski O; Chapron T; Capuano V; Souied EH Retina; 2017 Oct; 37(10):1873-1879. PubMed ID: 28079756 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography. Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes. Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal aflibercept for refractory choroidal neovascularization secondary to angioid streaks. Tetikoglu M; Sagdik HM; Aktas S; Ozcura F Eye (Lond); 2016 Jun; 30(6):894-5. PubMed ID: 26939555 [No Abstract] [Full Text] [Related]
10. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration. Lee GK; Lai TY; Chan WM; Lam DS Graefes Arch Clin Exp Ophthalmol; 2007 Aug; 245(8):1225-7. PubMed ID: 17287977 [TBL] [Abstract][Full Text] [Related]
11. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration. Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J; Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292 [TBL] [Abstract][Full Text] [Related]
13. Pigment epithelial tears after ranibizumab injection in polypoidal choroidal vasculopathy and typical age-related macular degeneration. Shin JY; Choi M; Chung B; Byeon SH Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2151-60. PubMed ID: 25744335 [TBL] [Abstract][Full Text] [Related]
14. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin): optical coherence tomography and fluorescein angiographic findings. Mathews JP; Jalil A; Lavin MJ; Stanga PE Eye (Lond); 2007 Jul; 21(7):1004-5. PubMed ID: 17479124 [No Abstract] [Full Text] [Related]